SUCCESS STORIES
‘Nectar - improving multidisciplinary care of mCRC patients’
‘Starting Families Asia’, the largest fertility study in APAC
Merck Serono has established a long term partnership with surgical and oncological key thought leaders across APAC to create an Asian Network of multidisciplinary care Centers for mCRC. This program is known as the NECTAR and partners with Prof Rene Adam in France with links to his LiverMet registry. The aim is to improve multidisciplinary care across the region to optimise management of potentially resectable mCRC patients among surgeons & medical oncologists.
The study is commissioned by Merck Serono and is conducted in collaboration with one of Asia’s leading fertility experts, Professor P. C. Wong from the National University Hospital in Singapore (NUH). It reveals key insights on the barriers and critical knowledge gaps that impact women and families regarding their ability and decision-making skills to conceive and start families.
The NECTAR group will define treatment protocols for the management of liver metastatic mCRC, collect and publish Asian data on mCRC patients, drive further awareness and education across the region via high quality preceptorship and scientific educational programs.
A survey was conducted across 1,000 women in 10 countries, who were trying to conceive. The objective was to gather insights into contemporary decisionmaking, regarding child conception and the barriers women and couples face, when they seek medical help during infertility.
India starts DReAMing
Diabetes Mellitus Registry for Antidiabetic Medications (DReAM), India is an ongoing, systematic listing of individuals with Type 2 diabetes. It is an observational, prospective, multi-centric database, which focuses on generating data on the epidemiological profile, clinical characteristics, investigational features and management trend of diabetic patients across the country. Merck Serono expects the campaign to lead India to an improved management of diabetes. It will further strengthen the Company’s image as leaders in the diabetes segment.
The study was modelled on a similar study undertaken by Merck Serono in collaboration with Cardiff University in 2009-2010. 19